Recruiting
Phase 2

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Sponsor:

Taiho Oncology, Inc.

Code:

NCT05727176

Conditions

Advanced Cholangiocarcinoma

FGFR2 Fusions

Gene Rearrangement

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TAS-120

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information